We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

Organizations that develop sophisticated approaches to IP risk management can protect their exit potential and create ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on BioNTech SE (BNTX – Research Report) today. The company’s shares ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...